Suggested remit: To appraise the clinical and cost effectiveness of Odevixibat (A 4250) within its marketing authorisation for treating progressive familial intrahepatic cholestasis.
Status In progress
Process HST
ID number 1570

Provisional Schedule

Committee meeting: 1 05 August 2021
Expected publication 22 January 2022

Project Team

Project lead Joanne Ekeledo

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Albireo (obevixibat)
Others Department of Health and Social Care
  NHS England
  Addenbrooke's Paediatric Gastrohepatology
  Birmingham Children’s Hospital NHS Foundation Trust
  Department of Endocrinology, University Hospital Birmingham Foundation Trust Paediatric Gastrohepatology
  King’s College Hospital NHS Foundation Trust
  Leeds Teaching Hospitals NHS Trust
  Great Ormond Street Paediatric Gastrohepatology
  Royal Free Paediatric Gastrohepatology
  Welsh Government
Patient carer groups Action for Sick Children
  Addenbrookes Liver Transplant Association
  British Liver Trust
  Children’s Liver Disease Foundation
  Genetic Alliance UK
  Metabolic Support UK
  Muslim Council of Great Britain
  National Children’s Bureau
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association for the Study of the Liver
  British Liver Nurses Forum
  British Society of Gastroenterology
  British Society of Paediatric Gastroenterology, Hepatology and Nutrition
  British Transplantation Society
  Neonatal and Paediatric Pharmacists Group
  Royal College of Physicians
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics and Child Health
  Royal Pharmaceutical Society
  UK Clinical Pharmacy Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services - Jehovah's Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  National Services Division (specialised services in Scotland)
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Hepato-Biliary Group
  Foundation for Liver Research
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  UK National Screening Committee


Key events during the development of the guidance:

Date Update
02 March 2021 Invitation to participate
02 March 2021 In progress. In progress
15 July 2020 - 12 August 2020 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance